Meet us at CPHI Milan 2026, Booth No. 10H33, Oct 6-8, Fiera Milano, Italy Schedule a Meeting
How Neuland optimized a complex rhodium-catalyzed asymmetric hydrogenation process, delivering exceptional purity, yield, and enantioselectivity at commercial scale.
In this case study, discover how Neuland partnered with a US-based pharmaceutical company to overcome the challenges of large-scale asymmetric hydrogenation for a key API intermediate in a Phase II autoimmune disease program. By leveraging deep expertise in catalytic chemistry, process optimization, and scale-up, Neuland successfully improved process robustness, reduced catalyst loading, enhanced safety, and demonstrated reliable manufacturing at the 100 kg scale while maintaining stringent quality requirements.
Achieved >99% purity at 100 kg manufacturing scale.
Delivered >99% enantioselectivity for the chiral process.
Maintained yields above 85% during scale-up.
Reduced rhodium catalyst loading to 0.05 mol%.
Lowered hydrogen pressure to improve process safety.
Established oxygen and moisture control procedures for catalyst handling.
Optimized cleaning and passivation practices.
Successfully scaled asymmetric hydrogenation from kilogram-scale development to 100 kg manufacturing.
This case study highlights how specialized expertise in asymmetric catalysis and process development can overcome complex stereochemical manufacturing challenges, improve operational safety, reduce costs, and deliver commercially scalable processes with exceptional quality and reproducibility
